Mylan (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mylan" in English language version.

refsWebsite

Global rank English rank

15nytimes.com

7^th place

11web.archive.org

1^st place

8fiercepharma.com

low place

8,921^st place

7bloomberg.com

99^th place

77^th place

6mylan.com

low place

6reuters.com

49^th place

47^th place

5pharmamedtechbi.com

low place

5fda.gov

447^th place

338^th place

4post-gazette.com

569^th place

354^th place

4nih.gov

4^th place

3bizjournals.com

407^th place

241^st place

3drugstorenews.com

low place

3doi.org

2^nd place

3latimes.com

22^nd place

19^th place

3wsj.com

79^th place

65^th place

3gizmodo.com

474^th place

329^th place

2sec.gov

572^nd place

436^th place

2marketwatch.com

1,303^rd place

808^th place

2books.google.com

3^rd place

2cnn.com

28^th place

26^th place

2indiatimes.com

17^th place

15^th place

2prnewswire.com

406^th place

258^th place

2fortune.com

433^rd place

284^th place

2genengnews.com

low place

6,625^th place

2forbes.com

54^th place

48^th place

2arstechnica.com

388^th place

265^th place

1medicalnewstoday.com

3,011^th place

2,709^th place

1triblive.com

2,497^th place

1,362^nd place

1fundinguniverse.com

1,333^rd place

957^th place

1nasdaq.com

2,740^th place

2,050^th place

1marketrealist.com

low place

1wvexecutive.com

low place

1thepharmaletter.com

low place

1law.edu

low place

1philly.com

664^th place

398^th place

1joc.com

low place

8,062^nd place

1ftc.gov

3,796^th place

2,268^th place

1barrons.com

2,737^th place

1,700^th place

1ihs.com

5,391^st place

3,206^th place

1icmrindia.org

low place

1pmlive.com

low place

1chicagotribune.com

95^th place

70^th place

1cbsnews.com

108^th place

80^th place

1justice.gov

918^th place

556^th place

1in-pharmatechnologist.com

low place

1pbs.org

198^th place

154^th place

1usatoday.com

41^st place

34^th place

1wboy.com

low place

1championforglobalhealth.com

low place

1biospace.com

low place

7,595^th place

1mrvirk.com

low place

1cbslocal.com

680^th place

412^th place

1science.org

1,160^th place

737^th place

1kpbs.org

8,474^th place

4,832^nd place

1money.com

9,129^th place

4,880^th place

1theguardian.com

12^th place

11^th place

1washingtonpost.com

34^th place

27^th place

1businessinsider.com

140^th place

115^th place

1nbcnews.com

137^th place

101^st place

1mercurynews.com

701^st place

439^th place

1bmj.com

1,226^th place

1,421^st place

1semanticscholar.org

11^th place

8^th place

1umn.edu

1,266^th place

860^th place

1investors.com

low place

6,516^th place

arstechnica.com (Global: 388^th place; English: 265^th place)

Mole, Beth (June 5, 2017). "Mylan chairman: Drug pricing critics ought to go copulate with themselves". Ars Technica.
Mole, Beth (October 7, 2016). "For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million". Ars Technica. Retrieved October 8, 2016.

barrons.com (Global: 2,737^th place; English: 1,700^th place)

Lazo, Shirley A. "Survival Strategy". Barron's.

biospace.com (Global: low place; English: 7,595^th place)

"Mylan's Merger with Pfizer's Off-Patent Drug Unit Will Create 'New Champion for Global Health'". BioSpace. July 29, 2019. Retrieved May 11, 2020.

bizjournals.com (Global: 407^th place; English: 241^st place)

Gough, Paul J. (November 16, 2020). "After nearly 60 years, Mylan makes way for Viatris". Pittsburgh Business Times. Retrieved December 10, 2020.
"Mylan buys part of drug maker". American City Business Journals. December 18, 2006.
Tascarella, Patty (February 27, 2015). "Mylan inversion deal completed". American City Business Journals.

bloomberg.com (Global: 99^th place; English: 77^th place)

"How Marketing Turned the EpiPen Into a Billion-Dollar Business". Bloomberg.com. Archived from the original on September 8, 2025. Retrieved December 24, 2025.
Koons, Cynthia (November 13, 2015). "Mylan's Hostile Bid for Perrigo Fails". Bloomberg.
"Teva to Buy Allergan's Generic Drug Unit". Bloomberg News. July 27, 2015.
Somayaji, Chitra (July 27, 2015). "Teva Snaps Up Allergan's Generics Arm, Dumping Mylan". Bloomberg News.
Larson, Erik; Hopkins, Jared S. (September 6, 2016). "Mylan's EpiPen School Sales Trigger N.Y. Antitrust Probe". Bloomberg. Retrieved September 7, 2016.
Feeley, Jef; Langreth, Robert (September 20, 2016). "Mylan Investigations Mount as West Virginia Opens Fraud Probe". Bloomberg News.
Tracer, Zachary (October 7, 2016). "Mylan Agrees to $465 Million EpiPen Settlement With U.S." Bloomberg.com.

bmj.com (Global: 1,226^th place; English: 1,421^st place)

Owen Dyer (October 24, 2014). "Drug company is targeted for refusing to adopt ban on distribution of execution drug". BMJ. 2014 (349) g6452. doi:10.1136/bmj.g6452. PMID 25344344. S2CID 21513100.

books.google.com (Global: 3^rd place; English: 3^rd place)

Seaman, John T.; Landry, John T. (April 10, 2012). Mylan: 50 Years of Unconventional Success: Making Quality Medicine Affordable and Accessible. UPNE. ISBN 978-1-61168-270-0.
John Seaman and John T. Landry. Mylan 50 Years of Unconventional Success. Mylan, in association with University Press of New England, 2011. ISBN 9781611682700. Page 50

businessinsider.com (Global: 140^th place; English: 115^th place)

Ramsey, Lydia (December 16, 2016). "The $300 generic EpiPen is here". Business Insider.

cbslocal.com (Global: 680^th place; English: 412^th place)

baltimore.cbslocal.com

Bartolotta, Devin (August 18, 2016). "Cost Jumps Nearly 500-Percent For Life-Saving EpiPens". CBS Baltimore. Retrieved August 19, 2016.

cbsnews.com (Global: 108^th place; English: 80^th place)

Edwards, Jim (July 28, 2009). "It's Not Mylan's First Quality Control Beef With FDA". CBS News.

championforglobalhealth.com (Global: low place; English: low place)

"Investor Presentations – August 2020 - Path to Shareholder Value Creation VIATRIS TSR Execution Plan" (PDF). Champion For Global Health. Retrieved October 22, 2020.

chicagotribune.com (Global: 95^th place; English: 70^th place)

Johnson, Carolyn Y.; Ho, Catherine (August 25, 2016). "How Mylan, the EpiPen company, maneuvered to create a virtual monopoly". The Chicago Tribune.

cnn.com (Global: 28^th place; English: 26^th place)

money.cnn.com

Creswell, Julie (March 21, 2005). "Icahn the Spoiler". Fortune.
Egan, Matt. "EpiPen maker faces revolt over exec's $98 million pay package". CNN Money.

doi.org (Global: 2^nd place; English: 2^nd place)

Boehm, Garth; Yao, Lixin; Han, Liang; Zheng, Qiang (September 2013). "Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984". Acta Pharmaceutica Sinica B. 3 (5): 297–311. doi:10.1016/j.apsb.2013.07.004.
Ku, Mannching Sherry (December 1, 2015). "Recent trends in specialty pharma business model". Journal of Food and Drug Analysis. 23 (4): 595–608. doi:10.1016/j.jfda.2015.04.008. PMC 9345453. PMID 28911475.
Owen Dyer (October 24, 2014). "Drug company is targeted for refusing to adopt ban on distribution of execution drug". BMJ. 2014 (349) g6452. doi:10.1136/bmj.g6452. PMID 25344344. S2CID 21513100.

drugstorenews.com (Global: low place; English: low place)

Dearment, Alaric (October 10, 2011). "Milan Puskar, co-founder of Mylan, dies". Drug Store News. Archived from the original on May 3, 2017. Retrieved September 8, 2016.
"Mylan acquires rights to Pfizer's inhaler technology". drugstorenews.com. Archived from the original on May 9, 2015.
"Milan Puskar, co-founder of Mylan, dies - Drug Store News". Drug Store News. October 10, 2011. Retrieved July 17, 2018.

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

FDA Approval History NDA 019129: Maxzide^{[dead link]} Page accessed September 8, 2016
"Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved July 17, 2018.^{[dead link]}
"Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved July 17, 2018.

fda.gov

"Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient" (Press release). Food and Drug Administration. December 4, 2018.
"FDA approves first generic Advair Diskus" (Press release). Food and Drug Administration. January 30, 2019. Archived from the original on December 15, 2019.

fiercepharma.com (Global: low place; English: 8,921^st place)

Helfand, Carly (February 22, 2016). "Mylan joins the Advair-copycat queue, but approval could be a long slog". Questex.
Palmer, Eric (August 18, 2015). "UPDATED: FDA castigates three Mylan sterile drug plants in warning letter". Questex.
"Mylan snaps up dermatology biz from investors in $1B deal". Questex. May 13, 2016.
Helfand, Carly (January 4, 2018). "Look out, Teva: Mylan's Copaxone copy has already captured serious share". Questex.
Blankenship, Kyle (November 12, 2019). "Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?". Questex.
Helfand, Carly (March 1, 2016). "FDA swats down Teva's EpiPen copy, putting Mylan in cruise control". Questex.
Bulik, Beth Snyder (May 1, 2016). "No holds barred in Mylan's ultra-realistic peanut allergy campaign". Questex.
Staton, Tracy (June 15, 2017). "As rebel Mylan investors win more backing, CEO Bresch champions her board". Questex.

forbes.com (Global: 54^th place; English: 48^th place)

Brozak, Steve (July 29, 2019). "What The Pfizer-Mylan Deal Means For Pharma". Forbes. Retrieved December 10, 2019.
Willingham, Emily (August 21, 2016). "Why Did Mylan Hike EpiPen Prices 400%? Because They Could". Forbes.

fortune.com (Global: 433^rd place; English: 284^th place)

WIECZNER, JEN (November 13, 2015). "Why Mylan Just Lost The Largest Hostile Takeover Battle Ever". Fortune.
"Why the CEO Behind the EpiPen Controversy Is on Fortune's Most Powerful Women List". Fortune.

ftc.gov (Global: 3,796^th place; English: 2,268^th place)

"Press release: FTC Reaches Record Financial Settlement To Settle Charges of Price-fixing in Generic Drug Market | Federal Trade Commission". FTC. November 29, 2000.

fundinguniverse.com (Global: 1,333^rd place; English: 957^th place)

"History of Mylan Laboratories Inc. – FundingUniverse". www.fundinguniverse.com. Retrieved June 11, 2018.

genengnews.com (Global: low place; English: 6,625^th place)

"Mylan to Co-Develop Pulmatrix' COPD Candidate". Mary Ann Liebert. June 16, 2015.
"Mylan to Acquire Meda for $9.9B". Mary Ann Liebert. February 11, 2016.

gizmodo.com (Global: 474^th place; English: 329^th place)

Novak, Matt (August 23, 2016). "How Congress, the FDA, and Sarah Jessica Parker Helped EpiPen Become a $1 Billion Business". Gizmodo.
Novak, Matt (June 5, 2017). "Drug Company Chairman to America: Go Fuck Yourself". Gizmodo.
Novak, Matt (August 23, 2016). "How Congress, the FDA, and Sarah Jessica Parker Helped EpiPen Become a $1 Billion Business". Gizmodo. Retrieved December 24, 2025.

icmrindia.org (Global: low place; English: low place)

"Mylan's Acquisition of Matrix: Business Strategy Case Study". ICRM.

ihs.com (Global: 5,391^st place; English: 3,206^th place)

"Mylan Signs US$736-mil. Takeover Deal for India's Matrix Laboratories". IHS. August 28, 2006.

in-pharmatechnologist.com (Global: low place; English: low place)

Stanton, Dan (June 8, 2015). "GSK breathes freely as Mylan launches Seretide generic in UK". in-Pharma Technologist.

indiatimes.com (Global: 17^th place; English: 15^th place)

economictimes.indiatimes.com

"US pharma major Mylan buys Matrix Labs". The Economic Times. August 29, 2006. Retrieved May 31, 2022.
"US drugmaker Mylan to acquire Famy Care for $750 Million". Times Internet. February 3, 2015.

investors.com (Global: low place; English: 6,516^th place)

GATLIN, ALLISON (September 22, 2017). "Generic Drug Makers Face Pricing Issues Unlike Other Pharmaceutical Companies". Investor's Business Daily.

joc.com (Global: low place; English: 8,062^nd place)

Reid, Kenneth (November 17, 1987). "US Judge to Rule on Drug Marketing". The Journal of Commerce.

justice.gov (Global: 918^th place; English: 556^th place)

"Four Pharmaceutical Companies Pay $124 Million for Submission of False Claims to Medicaid" (Press release). US Department of Justice. October 19, 2009.

kpbs.org (Global: 8,474^th place; English: 4,832^nd place)

Goldberg, Kenny (February 18, 2016). "People With Food Allergies Say Life-Saving Drug Too Expensive". KPBS Public Media.

latimes.com (Global: 22^nd place; English: 19^th place)

Cimons, Marlene (August 29, 1989). "FDA to Lift OK of Last Dyazide Generic Version". Los Angeles Times.
"Icahn Drops Bid for Mylan". Los Angeles Times. Bloomberg News. July 29, 2005.
Hiltzik, Michael (August 23, 2016). "Another reason to hate Mylan, which jacked up the price of life-saving EpiPens: It's a tax dodger". Los Angeles Times.

law.edu (Global: low place; English: low place)

scholarship.law.edu

Lewis, Ralph A. (1992). "The Emerging Effects of the Drug Price Competition and Patent Term Restoration Act of 1984". Journal of Contemporary Health Law & Policy. 8 (1): 361–378. PMID 10118987.

marketrealist.com (Global: low place; English: low place)

"Market Realist". marketrealist.com. October 5, 2017. Retrieved June 11, 2018.

marketwatch.com (Global: 1,303^rd place; English: 808^th place)

"Mylan N.V." MarketWatch. Retrieved June 11, 2018.
Court, Emma (August 18, 2016). "Mylan's EpiPen price increases are Valeant-like in size, Shkreli-like in approach". MarketWatch.

medicalnewstoday.com (Global: 3,011^th place; English: 2,709^th place)

"Mylan Laboratories To Acquire Generics Business Of Merck KGaA For 4.9 Billion Euros". Medical News Today. May 26, 2007. Archived from the original on February 24, 2008. Retrieved January 28, 2010.

mercurynews.com (Global: 701^st place; English: 439^th place)

Tracy, Seipel. "Silicon Valley engineers figure real cost to make lifesaving auto-injector two-pack". The Mercury News. Retrieved October 1, 2016.

money.com (Global: 9,129^th place; English: 4,880^th place)

Tuttle, Brad (August 22, 2016). "5 Signs That EpiPen Prices Are Completely Out of Control". Money.com. Archived from the original on May 25, 2022.

mrvirk.com (Global: low place; English: low place)

"Mylan Upjohn Merger – Pfizer Shareholders to receive 0.12 Viatris Shares per Pfizer Share". Mr. Virk Media. November 17, 2020.

mylan.com (Global: low place; English: low place)

nasdaq.com (Global: 2,740^th place; English: 2,050^th place)

"iShares Nasdaq Biotechnology Index Fund (IBB)". NASDAQ.com. Retrieved June 11, 2018.

nbcnews.com (Global: 137^th place; English: 101^st place)

Popken, Ben (September 30, 2016). "Upgraded EpiPens torn apart. Tech firm: "It's the same core device"". NBC News.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Lewis, Ralph A. (1992). "The Emerging Effects of the Drug Price Competition and Patent Term Restoration Act of 1984". Journal of Contemporary Health Law & Policy. 8 (1): 361–378. PMID 10118987.
Ku, Mannching Sherry (December 1, 2015). "Recent trends in specialty pharma business model". Journal of Food and Drug Analysis. 23 (4): 595–608. doi:10.1016/j.jfda.2015.04.008. PMC 9345453. PMID 28911475.
Owen Dyer (October 24, 2014). "Drug company is targeted for refusing to adopt ban on distribution of execution drug". BMJ. 2014 (349) g6452. doi:10.1136/bmj.g6452. PMID 25344344. S2CID 21513100.

ncbi.nlm.nih.gov

Ku, Mannching Sherry (December 1, 2015). "Recent trends in specialty pharma business model". Journal of Food and Drug Analysis. 23 (4): 595–608. doi:10.1016/j.jfda.2015.04.008. PMC 9345453. PMID 28911475.

nytimes.com (Global: 7^th place; English: 7^th place)

nytimes.com

Freudenheim, Milt (September 10, 1989). "Exposing the F.D.A.". The New York Times.
"COMPANY NEWS; SmithKline Loses Drug Exclusivity". The New York Times. Reuters. August 22, 1987.
Strickland, Carol (October 15, 1989). "Bolar: A Drug Company Under Siege". The New York Times.
Freudenheim, Milt (February 28, 1991). "Bolar Plans Guilty Plea On Generics". The New York Times.
Andrews, Edmund L. (July 31, 1989). "F.D.A. Inquiry on Generic Drugs Focuses on Changes in Ingredients". The New York Times.
Labaton, Stephen (December 5, 1998). "A Drug Maker Is Said to Face A Suit on Prices". The New York Times.
Labaton, Stephen (July 13, 2000). "Generic-Drug Maker Agrees to Settlement In Price-Fixing Case". The New York Times.
Pollack, Andrew (November 20, 2004). "Icahn Offers $5.4 Billion for Mylan, Drug Maker". The New York Times.
O'keefe, Eric (May 12, 2005). "Icahn Slate Wins Seats on Blockbuster Board". The New York Times.
Thomas, Katie (December 15, 2016). "20 States Accuse Generic Drug Companies of Price Fixing". The New York Times.
Duhigg, Charles (June 4, 2017). "Outcry Over EpiPen Prices Hasn't Made Them Lower". The New York Times.
Thomas, Katie (October 7, 2016). "Mylan to Settle EpiPen Overpricing Case for $465 Million". The New York Times.
Thomas, Katie (September 2, 2016). "Is EpiPen a Brand-Name or a Generic Drug? Mylan Casts It Both Ways". The New York Times.

dealbook.nytimes.com

Thomas, Katie (February 27, 2013). "Mylan Buys Drug Maker of Generic Injectables". The New York Times.

well.blogs.nytimes.com

Parker-Pope, Tara; Peachman, Rachel Rabkin (August 22, 2016). "EpiPen Price Rise Sparks Concern for Allergy Sufferers". The New York Times.

pbs.org (Global: 198^th place; English: 154^th place)

Swetlitz, Ike; Silverman, Ed (August 26, 2016). "Mylan may have violated antitrust law in its EpiPen sales to schools". PBS Newshour.

pharmamedtechbi.com (Global: low place; English: low place)

pink.pharmamedtechbi.com

Pink Sheet October 22, 1984 Mylan's Maxzide is "Approvable" at FDA: Lederle To Market Brand Competition to Smithkline's No. 3-Ranked Dyazide; Final Approval Anticipated "Imminently"
"Bolar and Mylan Team to Purchase Somerset Labs". Pink Sheet. November 14, 1988.
"Somerset Eldepryl June 5 Approval Clears Way For Mylan/Bolar Acquisition". Pink Sheet. June 12, 1989.
"MYLAN's MAXZIDE IS "APPROVABLE" AT FDA: LEDERLE TO MARKET BRAND COMPETITION TO SMITHKLINE's No. 3-RANKED DYAZIDE; FINAL APPROVAL ANTICIPATED "IMMINENTLY"". Pink Sheet. October 22, 1984. Retrieved July 17, 2018.
"SOMERSET ELDEPRYL JUNE 5 APPROVAL CLEARS WAY FOR MYLAN/BOLAR ACQUISITION". Pink Sheet. June 12, 1989. Retrieved July 17, 2018.

philly.com (Global: 664^th place; English: 398^th place)

articles.philly.com

Shaw, Donna (February 27, 1991). "U.s. Charges Bolar Pharmaceutical With Misrepresenting Its Products". Philadelphia Inquirer. Archived from the original on September 16, 2016.

pmlive.com (Global: low place; English: low place)

"Mylan completes acquisition of Merck's generic unit". PM Live. September 30, 2008.

post-gazette.com (Global: 569^th place; English: 354^th place)

Massey, Steve (May 13, 2007). "Mylan buys Merck generic drug unit for $6.6 billion". Pittsburgh Post-Gazette.
Sabatini, Patricia; Boselovic, Len (July 26, 2009). "Mylan workers overrode drug quality controls Internal report detailed 'pervasive' practice of ignoring safety procedures". Pittsburgh Post-Gazette.
"Drug company Mylan, Post-Gazette resolve lawsuits". post-gazette.com.
Sabatini, Patricia (November 12, 2019). "Viatris picked as new name for a merged Mylan/Upjohn". Pittsburgh Post-Gazette.

prnewswire.com (Global: 406^th place; English: 258^th place)

"Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business" (Press release). Business Wire. February 27, 2015.
King Pharmaceuticals October 21, 2002. Press Release: King Pharmaceuticals to Acquire Meridian Medical Technologies

reuters.com (Global: 49^th place; English: 47^th place)

reuters.com

Kareen Nair, Samantha (November 13, 2015). "Mylan fails in $26 billion takeover bid for Perrigo". Reuters.
Erman, Michael (May 31, 2017). "Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS". Reuters. New York. Retrieved May 31, 2017.
Kusjanto, Mantik. "Merck KGaA sells generics unit to Mylan for $6.6 bln". U.S. Retrieved July 17, 2018.

uk.reuters.com

Ponnezhath, Maria (July 27, 2019). "Pfizer in talks to merge off-patent drugs business with Mylan: source". Reuters. Archived from the original on July 27, 2019.
"Pfizer to spinoff, [sic] merge off-patent drugs unit with Mylan". Reuters. July 29, 2019. Archived from the original on July 29, 2019. Retrieved May 11, 2020.

fr.reuters.com

Nathan, Vidya L. (February 3, 2015). "Mylan buys female health businesses from Indian drugmaker". Reuters.^{[dead link]}

science.org (Global: 1,160^th place; English: 737^th place)

Loew, Derek (June 12, 2017). "Mylan Begins Harvesting the Crop It's Sown". Science.

sec.gov (Global: 572^nd place; English: 436^th place)

"FORM 10-K".
"10-K". www.sec.gov. Retrieved December 24, 2025.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Owen Dyer (October 24, 2014). "Drug company is targeted for refusing to adopt ban on distribution of execution drug". BMJ. 2014 (349) g6452. doi:10.1136/bmj.g6452. PMID 25344344. S2CID 21513100.

theguardian.com (Global: 12^th place; English: 11^th place)

"Mylan to provide EpiPen cost assistance as CEO is asked to testify on price hike". The Guardian. August 25, 2016.

thepharmaletter.com (Global: low place; English: low place)

"Mylan Laboratories". www.thepharmaletter.com.

triblive.com (Global: 2,497^th place; English: 1,362^nd place)

archive.triblive.com

"Pharmaceutical giants tracking Mylan's prosperity". The Pittsburgh Tribune-Review. August 13, 2008. Archived from the original on September 8, 2008.

umn.edu (Global: 1,266^th place; English: 860^th place)

cidrap.umn.edu

"FDA approves generic forms of ciprofloxacin". CIDRAP. Retrieved July 17, 2018.

usatoday.com (Global: 41^st place; English: 34^th place)

O'Donnell, Jayne (September 21, 2016). "Family matters: EpiPens had high-level help getting into schools". USA Today.

washingtonpost.com (Global: 34^th place; English: 27^th place)

Carolyn Y. Johnson (August 25, 2016). "Why Mylan's 'savings card' won't make EpiPen cheaper for all patients". The Washington Post.

wboy.com (Global: low place; English: low place)

Hudock, Megan (May 14, 2018). "Mylan and WVU announce 10 year collaboration". WBOY-TV.

web.archive.org (Global: 1^st place; English: 1^st place)

"Mylan Laboratories To Acquire Generics Business Of Merck KGaA For 4.9 Billion Euros". Medical News Today. May 26, 2007. Archived from the original on February 24, 2008. Retrieved January 28, 2010.
"Pharmaceutical giants tracking Mylan's prosperity". The Pittsburgh Tribune-Review. August 13, 2008. Archived from the original on September 8, 2008.
Dearment, Alaric (October 10, 2011). "Milan Puskar, co-founder of Mylan, dies". Drug Store News. Archived from the original on May 3, 2017. Retrieved September 8, 2016.
Shaw, Donna (February 27, 1991). "U.s. Charges Bolar Pharmaceutical With Misrepresenting Its Products". Philadelphia Inquirer. Archived from the original on September 16, 2016.
"Press release: Mylan Completes Acquisition of Generics Business of Merck KGaA". Mylan. October 2, 2007. Archived from the original on June 19, 2018. Retrieved September 8, 2016.
"How Marketing Turned the EpiPen Into a Billion-Dollar Business". Bloomberg.com. Archived from the original on September 8, 2025. Retrieved December 24, 2025.
"Mylan acquires rights to Pfizer's inhaler technology". drugstorenews.com. Archived from the original on May 9, 2015.
"FDA approves first generic Advair Diskus" (Press release). Food and Drug Administration. January 30, 2019. Archived from the original on December 15, 2019.
Ponnezhath, Maria (July 27, 2019). "Pfizer in talks to merge off-patent drugs business with Mylan: source". Reuters. Archived from the original on July 27, 2019.
"Pfizer to spinoff, [sic] merge off-patent drugs unit with Mylan". Reuters. July 29, 2019. Archived from the original on July 29, 2019. Retrieved May 11, 2020.
Tuttle, Brad (August 22, 2016). "5 Signs That EpiPen Prices Are Completely Out of Control". Money.com. Archived from the original on May 25, 2022.

wsj.com (Global: 79^th place; English: 65^th place)

Adams, Russell (October 30, 2009). "Mylan Again Sues Pittsburgh Post-Gazette". The Wall Street Journal.
Rockoff, Jonathan D.; Mattioli, Dana (April 22, 2015). "Teva Offers to Buy Mylan for $40 Billion". The Wall Street Journal.
Walker, Joseph; Winslow, Ron; Steele, Anne (August 30, 2016). "Mylan to Launch Cheaper Generic EpiPen Alternative". The Wall Street Journal.

wvexecutive.com (Global: low place; English: low place)

"A Tale of Two Entrepreneurs". www.wvexecutive.com. Retrieved July 1, 2018.

Mylan (English Wikipedia)

arstechnica.com (Global: 388th place; English: 265th place)

barrons.com (Global: 2,737th place; English: 1,700th place)

biospace.com (Global: low place; English: 7,595th place)

bizjournals.com (Global: 407th place; English: 241st place)

bloomberg.com (Global: 99th place; English: 77th place)

bmj.com (Global: 1,226th place; English: 1,421st place)

books.google.com (Global: 3rd place; English: 3rd place)

businessinsider.com (Global: 140th place; English: 115th place)

cbslocal.com (Global: 680th place; English: 412th place)

baltimore.cbslocal.com

cbsnews.com (Global: 108th place; English: 80th place)

championforglobalhealth.com (Global: low place; English: low place)

chicagotribune.com (Global: 95th place; English: 70th place)

cnn.com (Global: 28th place; English: 26th place)

money.cnn.com

doi.org (Global: 2nd place; English: 2nd place)

drugstorenews.com (Global: low place; English: low place)

fda.gov (Global: 447th place; English: 338th place)

accessdata.fda.gov

fda.gov

fiercepharma.com (Global: low place; English: 8,921st place)

forbes.com (Global: 54th place; English: 48th place)

fortune.com (Global: 433rd place; English: 284th place)

ftc.gov (Global: 3,796th place; English: 2,268th place)

fundinguniverse.com (Global: 1,333rd place; English: 957th place)

genengnews.com (Global: low place; English: 6,625th place)

gizmodo.com (Global: 474th place; English: 329th place)

icmrindia.org (Global: low place; English: low place)

ihs.com (Global: 5,391st place; English: 3,206th place)

in-pharmatechnologist.com (Global: low place; English: low place)

indiatimes.com (Global: 17th place; English: 15th place)

economictimes.indiatimes.com

investors.com (Global: low place; English: 6,516th place)

joc.com (Global: low place; English: 8,062nd place)

justice.gov (Global: 918th place; English: 556th place)

kpbs.org (Global: 8,474th place; English: 4,832nd place)

latimes.com (Global: 22nd place; English: 19th place)

law.edu (Global: low place; English: low place)

scholarship.law.edu

marketrealist.com (Global: low place; English: low place)

marketwatch.com (Global: 1,303rd place; English: 808th place)

medicalnewstoday.com (Global: 3,011th place; English: 2,709th place)

mercurynews.com (Global: 701st place; English: 439th place)

money.com (Global: 9,129th place; English: 4,880th place)

mrvirk.com (Global: low place; English: low place)

mylan.com (Global: low place; English: low place)

mylan.com

newsroom.mylan.com

investor.mylan.com

nasdaq.com (Global: 2,740th place; English: 2,050th place)

nbcnews.com (Global: 137th place; English: 101st place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nytimes.com (Global: 7th place; English: 7th place)

nytimes.com

dealbook.nytimes.com

well.blogs.nytimes.com

pbs.org (Global: 198th place; English: 154th place)

pharmamedtechbi.com (Global: low place; English: low place)

pink.pharmamedtechbi.com

philly.com (Global: 664th place; English: 398th place)

articles.philly.com

pmlive.com (Global: low place; English: low place)

post-gazette.com (Global: 569th place; English: 354th place)

prnewswire.com (Global: 406th place; English: 258th place)

reuters.com (Global: 49th place; English: 47th place)

reuters.com

uk.reuters.com

fr.reuters.com

science.org (Global: 1,160th place; English: 737th place)

sec.gov (Global: 572nd place; English: 436th place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

theguardian.com (Global: 12th place; English: 11th place)

thepharmaletter.com (Global: low place; English: low place)

triblive.com (Global: 2,497th place; English: 1,362nd place)

archive.triblive.com

umn.edu (Global: 1,266th place; English: 860th place)

arstechnica.com (Global: 388^th place; English: 265^th place)

barrons.com (Global: 2,737^th place; English: 1,700^th place)

biospace.com (Global: low place; English: 7,595^th place)

bizjournals.com (Global: 407^th place; English: 241^st place)

bloomberg.com (Global: 99^th place; English: 77^th place)

bmj.com (Global: 1,226^th place; English: 1,421^st place)

books.google.com (Global: 3^rd place; English: 3^rd place)

businessinsider.com (Global: 140^th place; English: 115^th place)

cbslocal.com (Global: 680^th place; English: 412^th place)

cbsnews.com (Global: 108^th place; English: 80^th place)

chicagotribune.com (Global: 95^th place; English: 70^th place)

cnn.com (Global: 28^th place; English: 26^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

fda.gov (Global: 447^th place; English: 338^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

forbes.com (Global: 54^th place; English: 48^th place)

fortune.com (Global: 433^rd place; English: 284^th place)

ftc.gov (Global: 3,796^th place; English: 2,268^th place)

fundinguniverse.com (Global: 1,333^rd place; English: 957^th place)

genengnews.com (Global: low place; English: 6,625^th place)

gizmodo.com (Global: 474^th place; English: 329^th place)

ihs.com (Global: 5,391^st place; English: 3,206^th place)

indiatimes.com (Global: 17^th place; English: 15^th place)

investors.com (Global: low place; English: 6,516^th place)

joc.com (Global: low place; English: 8,062^nd place)

justice.gov (Global: 918^th place; English: 556^th place)

kpbs.org (Global: 8,474^th place; English: 4,832^nd place)

latimes.com (Global: 22^nd place; English: 19^th place)

marketwatch.com (Global: 1,303^rd place; English: 808^th place)

medicalnewstoday.com (Global: 3,011^th place; English: 2,709^th place)

mercurynews.com (Global: 701^st place; English: 439^th place)

money.com (Global: 9,129^th place; English: 4,880^th place)

nasdaq.com (Global: 2,740^th place; English: 2,050^th place)

nbcnews.com (Global: 137^th place; English: 101^st place)

nih.gov (Global: 4^th place; English: 4^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

pbs.org (Global: 198^th place; English: 154^th place)

philly.com (Global: 664^th place; English: 398^th place)

post-gazette.com (Global: 569^th place; English: 354^th place)

prnewswire.com (Global: 406^th place; English: 258^th place)

reuters.com (Global: 49^th place; English: 47^th place)

science.org (Global: 1,160^th place; English: 737^th place)

sec.gov (Global: 572^nd place; English: 436^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

theguardian.com (Global: 12^th place; English: 11^th place)

triblive.com (Global: 2,497^th place; English: 1,362^nd place)

umn.edu (Global: 1,266^th place; English: 860^th place)

usatoday.com (Global: 41^st place; English: 34^th place)

washingtonpost.com (Global: 34^th place; English: 27^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

wsj.com (Global: 79^th place; English: 65^th place)